We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Faron Pharmaceuticals Oy | LSE:FARN | London | Ordinary Share | FI4000153309 | ORD NPV (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 127.50 | 110.00 | 135.00 | 0.00 | 07:34:23 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -28.73M | -0.4177 | -3.05 | 87.7M |
TIDMFARN
RNS Number : 1926S
Faron Pharmaceuticals Oy
21 June 2018
Faron Pharmaceuticals Oy
("Faron" or the "Company")
PDMR Dealings and
Person Closely Associated with PDMR Dealings
TURKU - FINLAND, 21 June 2018 - Faron Pharmaceuticals Ltd ("Faron") (LON: FARN), the clinical stage biopharmaceutical company, announces that on 21 June 2018 it was notified of the following PDMR and persons closely associated dealings.
On 19 June 2018, Mr Matti Manner, the Non-Executive Director of Faron had acquired 15,500 ordinary shares in Faron at a price of 56 pence per ordinary share, and a person closely associated with him had acquired 7,900 ordinary shares in Faron at a price of 56 pence per ordinary share.
On 20 June 2018, Mr Yrjö Wichmann, Chief Financial Officer of Faron had acquired 5,200 ordinary shares in Faron at a price of 67 pence per ordinary share and on 21 June 2018, Dr. Pessi Honkasalo, Corporate Legal Counsel of Faron had acquired 1,500 ordinary shares in Faron at a price of 75 pence per ordinary share.
On 21 June 2018, Dr Matti Karvonen, Medical Director of Faron, had acquired 15,000 ordinary shares in Faron at a price of 56 pence per ordinary share and a person closely associated with him had acquired 31,000 ordinary shares in Faron at a price of 57 pence per ordinary share.
On 21 June 2018, Dr. Markku Jalkanen, Chief Executive Officer of Faron, had acquired 12,000 ordinary shares and a person closely associated with him had acquired 24,000 ordinary shares in Faron at a price of 71 pence per ordinary share. Also on 21 June 2018, Dr. Juho Jalkanen, Chief Development Officer of Faron had acquired 12,000 ordinary shares in Faron at a price of 71 pence per ordinary share.
The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 1 Details of the person discharging managerial responsibilities/person closely associated ---- ----------------------------------------------------------------------------------------- a. Name Matti Manner Susanna Hedenström Yrjö Wichmann Pessi Honkasalo Matti Karvonen Minja Pfeiffer Markku Jalkanen Mehto Saima Kuolinpesä Juho Jalkanen ------------------------------------------------------------ 2 Reason for notification --------------------------- ------------------------------------------------------------ a. Position/Status Person discharging managerial responsibilities / person closely associated - Non-Executive Director and a person closely associated with him - Chief Financial Officer - Corporate Legal Counsel - Medical Director and a person closely associated with him - Chief Executive Officer and a person closely associated with him - Chief Development Officer --------------------------- ------------------------------------------------------------ b. Initial notification/ Initial Notification Amendment --------------------------- ------------------------------------------------------------ 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ----------------------------------------------------------------------------------------- a. Name Faron Pharmaceuticals Oy --------------------------- b. LEI 7437009H31TO1DC0EB42 --------------------------- ------------------------------------------------------------ 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ---- ----------------------------------------------------------------------------------------- a. Description of Ordinary shares the financial instrument, type ISIN: FI4000153309 of instrument Identification Code --------------------------- ------------------------------------------------------------ b. Nature of the Purchase of ordinary shares transaction --------------------------- ------------------------------------------------------------ c. Price(s) and volume(s) Price(s) Volume(s) --------------------------- --------------- 56.00 GBPp 15,500 56.00 GBPp 7,900 67.00 GBPp 5,200 75.00 GBPp 1,500 56.00 GBPp 15,000 57.00 GBPp 31,000 71.00 GBPp 12,000 71.00 GBPp 24,000 71.00 GBPp 12,000 ----------------------------------------------------- ------------ d. Aggregated information - Aggregated Volume N/A - Price N/A --------------------------- ------------------------------------------------------------ e. Date of the transaction June 19, 2018, June 20, 2018 and June 21, 2018 --------------------------- ------------------------------------------------------------ f. Place of the transaction London Stock Exchange, AIM Market --------------------------- ------------------------------------------------------------
For more information please contact:
Faron Pharmaceuticals Ltd
Dr Markku Jalkanen, Chief Executive Officer
investor.relations@faron.com
Consilium Strategic Communications
Mary-Jane Elliott, Philippa Gardner, Matthew Neal, Lindsey Neville
Phone: +44 (0)20 3709 5700
E-mail: faron@consilium-comms.com
Westwicke Partners, IR (US)
Chris Brinzey
Phone: 01 339 970 2843
E-Mail: chris.brinzey@westwicke.com
Panmure Gordon (UK) Limited, Nomad and Broker
Freddy Crossley, Emma Earl, Ryan McCarthy
Phone: +44 207 886 2500
About Faron Pharmaceuticals Ltd
Faron (AIM:FARN) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy. The Company's lead candidate Traumakine, to prevent vascular leakage and organ failures, has completed a Phase III clinical trial in Acute Respiratory Distress Syndrome ("ARDS"). An additional European Phase II Traumakine trial is underway for the Rupture of Abdominal Aorta Aneurysm ("RAAA"). Faron's second candidate Clevegen is a ground breaking preclinical anti-Clever-1 antibody. Clevegen has the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. This novel macrophage-directed immuno-oncology switch called Tumour Immunity Enabling Technology ("TIET") may be used alone or in combination with other immune checkpoint molecules for the treatment of cancer patients. Faron is based in Turku, Finland. Further information is available at www.faron.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHFKDDPQBKDAAB
(END) Dow Jones Newswires
June 21, 2018 10:58 ET (14:58 GMT)
1 Year Faron Pharmaceuticals Oy Chart |
1 Month Faron Pharmaceuticals Oy Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions